Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
REVOX Studio has launched a new AI Agent framework

REVOX Studio has launched a new AI Agent framework

X2024/12/30 06:03

On December 26, REVOX Studio launched an innovative AI Agent framework to provide developers with low-code development support, multimodal intelligent interaction, and cutting-edge technologies such as DPrompt and zkML verification. This platform aims to help developers optimize decentralized finance (DeFi) and smart contract applications through intelligent tools.

The main functional highlights of REVOX Studio include: 1. Redefine DeFi applications: realize token issuance, spot and perpetual transactions, and cross-chain interoperability. 2. On-chain autonomous intelligent system: provide transparent and efficient solutions for asset management, community participation, etc. 3. Modular smart contract ecology: support seamless integration of on-chain and off-chain data, and promote cross-domain innovation. With REVOX Studio, users can easily complete tasks such as token staking and liquidity management using natural language, greatly reducing the technical threshold. In addition, the platform also supports AI-driven fair Meme issuance, bringing more imagination to decentralized applications.

2
1

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Laser uranium enrichment technology developer LIS Technologies (LIS.US) sets IPO price at $5-7 per share, aiming to raise $17 million

LIS Technologies plans to issue 2.8 million shares at a price range of $5 to $7 per share to raise $17 million.

智通财经•2026/10/27 07:27
Laser uranium enrichment technology developer LIS Technologies (LIS.US) sets IPO price at $5-7 per share, aiming to raise $17 million

Immunology and inflammation biotech company Bambusa (BBTX.US) prices IPO at $15-17 per share, aims to raise $150 million.

Bambusa Therapeutics plans to raise 150 millions USD by issuing 9.4 million shares at a price range of 15 to 17 USD per share.

智通财经•2026/10/27 07:21

The Bank of Japan’s price trend indicator rises above 3%, providing grounds for further rate hikes

The Bank of Japan's indicator for measuring underlying inflation has risen to its highest level in three years, far surpassing the bank's 2% target, providing grounds for authorities to continue raising interest rates.

智通财经•2026/10/27 07:17
The Bank of Japan’s price trend indicator rises above 3%, providing grounds for further rate hikes